Neonc Technologies, Inc.
NTHI · Nasdaq · United States
Share price · NTHI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NTHI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+16.8%
- 8 Sep 2026-19.1%
Nothing announced by NTHI that day or the session before.
- 19 Aug 2026-16.3%
Nothing announced by NTHI that day or the session before.
- 14 Aug 2026+31.5%
- 12 Aug 2026-20.5%
- 11 Aug 2026+24.3%
- 14 Jul 2026-14.8%
Nothing announced by NTHI that day or the session before.
- 16 Jun 2026+14.9%
- 8 May 2026-16.0%
Nothing announced by NTHI that day or the session before.
- 7 May 2026+22.2%
Nothing announced by NTHI that day or the session before.
Share of unusual movement by asset
For each asset, the share of NTHI's own-move activity since 27 Mar 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (9)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $1.3M | $6.2M | $4.4M-$5.1M operating cash flow | report ↗ |
View 8 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $2.6M | $2.0M | $14M-$4.8M operating cash flow | report ↗ |
| 2026-Q1 | — | $1.3M | $0.1M | $8.8M-$7.0M operating cash flow | report ↗ |
| 2025-Q3 | — | $0.7M | $1.5M | $8.6M-$5.8M operating cash flow | report ↗ |
| 2025-Q2 | — | $0.7M | $0.1M | $5.7M-$5.3M operating cash flow | report ↗ |
| 2025-Q1 | <$0.1M | $1.0M | $5.4M | $38M-$5.7M operating cash flow | report ↗ |
| 2024-Q3 | — | $1.0M | $1.3M | $2.2M-$3.1M operating cash flow | report ↗ |
| 2024-Q2 | <$0.1M | $0.4M | $1.5M | $4.5M-$0.3M operating cash flow | report ↗ |
| 2024-Q1 | <$0.1M | $0.6M | <$0.1M | $2.9M$0.1M operating cash flow | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | <$0.1M | $3.6M | $0.1M | $16M-$20M operating cash flow | report ↗ |
Neonc Technologies reported revenue of $0.04M for fiscal year 2025, down 50.0% YoY, with R&D spend of $3.64M, up 19.3% YoY. The company ended the year with cash and equivalents of $0.06M and recorded a net loss of $62.15M, equating to a quarterly net burn of $62.15M.
The clinical-stage company is advancing intranasal NEO100 in a Phase IIa trial for recurrent IDH-mutant grade III/IV gliomas (20 patients enrolled) and a Phase II study in high-grade meningioma (6 patients enrolled), while the NEO212-01 Phase 1/2 dose-escalation portion was completed with the maximum tolerated dose reached at Cohort 5 (810 mg) and a recommended Phase 2 dose of 610 mg. In 2025, Neonc also acquired an artificial intelligence-driven drug discovery and 3D bioprinting intellectual property portfolio for approximately $3.5 million.
Insider transactions
Open-market activity, trailing 12 months: 38 purchases ($2.2M), 1 sale ($17K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Heshmatpour Amir F · director, CEO, President, 10% owner | Open-market purchase | 30,000 | $5.02 | $151K | Form 4 |
| 2026-11-11 | Heshmatpour Amir F · director, CEO, President, 10% owner | Open-market purchase | 10,000 | $4.49 | $45K | Form 4 |
| 2026-11-11 | Heshmatpour Amir F · director, CEO, President, 10% owner | Open-market purchase | 10,000 | $4.00 | $40K | Form 4 |
| 2026-11-10 | Heshmatpour Amir F · director, CEO, President, 10% owner | Open-market purchase | 50,000 | $4.19 | $210K | Form 4 |
| 2026-11-10 | CHEN THOMAS C · director, CMO, 10% owner | Open-market purchase | 2,284 | $4.38 | $10K | Form 4 |
| 2026-11-09 | CHEN THOMAS C · director, CMO, 10% owner | Open-market purchase | 2,732 | $3.66 | $10K | Form 4 |
| 2026-11-09 | Heshmatpour Amir F · director, CEO, President, 10% owner | Open-market purchase | 10,000 | $3.86 | $39K | Form 4 |
| 2026-11-06 | Heshmatpour Amir F · director, CEO, President, 10% owner | Open-market purchase | 40,000 | $3.39 | $136K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 26 reporting institutions held 2.9M shares ($20.2M, 11.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Cinctive Capital Management LP | 1,425,526 | $10.0M |
| 2 | BANK OF AMERICA CORP /DE/ | 235,396 | $1.7M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 215,700 | $1.5M |
| 4 | BlackRock, Inc. | 155,838 | $1.1M |
| 5 | Hudson Bay Capital Management LP | 147,360 | $962K |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 126,853 | $890K |
| 7 | MILLENNIUM MANAGEMENT LLC | 119,249 | $836K |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 91,036 | $638K |
| 9 | VANGUARD FIDUCIARY TRUST CO | 56,016 | $393K |
| 10 | MORGAN STANLEY | 51,922 | $364K |
| 11 | 683 Capital Management, LLC | 50,000 | $351K |
| 12 | Westmount Partners, LLC | 43,320 | $304K |
| 13 | STATE STREET CORP | 43,170 | $303K |
| 14 | GOLDMAN SACHS GROUP INC | 35,580 | $249K |
| 15 | NORTHERN TRUST CORP | 23,271 | $163K |